Business Description
BGI Genomics Co Ltd
ISIN : CNE100003449
Share Class Description:
SZSE:300676: Class ACompare
Compare
Traded in other countries / regions
300676.China IPO Date
2017-07-14Description
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.7 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -34.77 | |||||
| Interest Coverage | 0.95 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.59 | |||||
| Beneish M-Score | -2.17 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -20.5 | |||||
| 3-Year EBITDA Growth Rate | -39.6 | |||||
| 3-Year EPS without NRI Growth Rate | -64.7 | |||||
| 3-Year Book Growth Rate | 17.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.46 | |||||
| 9-Day RSI | 42.16 | |||||
| 14-Day RSI | 47.06 | |||||
| 6-1 Month Momentum % | 19.17 | |||||
| 12-1 Month Momentum % | -7.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.63 | |||||
| Quick Ratio | 2.38 | |||||
| Cash Ratio | 1.64 | |||||
| Days Inventory | 108.74 | |||||
| Days Sales Outstanding | 146.62 | |||||
| Days Payable | 152.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.22 | |||||
| Dividend Payout Ratio | 0.8 | |||||
| 3-Year Dividend Growth Rate | 114.7 | |||||
| Forward Dividend Yield % | 0.22 | |||||
| 5-Year Yield-on-Cost % | 0.74 | |||||
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | 0.36 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.88 | |||||
| Operating Margin % | 1.75 | |||||
| Net Margin % | -2.52 | |||||
| FCF Margin % | -14.16 | |||||
| ROE % | -1.02 | |||||
| ROA % | -0.76 | |||||
| ROIC % | 1.04 | |||||
| ROC (Joel Greenblatt) % | -0.71 | |||||
| ROCE % | -0.23 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 107.55 | |||||
| PE Ratio without NRI | 361.36 | |||||
| Shiller PE Ratio | 26.57 | |||||
| PEG Ratio | 48.83 | |||||
| PS Ratio | 4.61 | |||||
| PB Ratio | 1.91 | |||||
| Price-to-Tangible-Book | 2.05 | |||||
| Price-to-Operating-Cash-Flow | 198.62 | |||||
| EV-to-EBIT | -626.88 | |||||
| EV-to-EBITDA | -626.88 | |||||
| EV-to-Revenue | 3.7 | |||||
| EV-to-FCF | -25.71 | |||||
| Price-to-Projected-FCF | 1.65 | |||||
| Price-to-Graham-Number | 5.73 | |||||
| Price-to-Net-Current-Asset-Value | 4.56 | |||||
| Price-to-Net-Cash | 14.96 | |||||
| Earnings Yield (Greenblatt) % | -0.16 | |||||
| FCF Yield % | -3.04 | |||||
| Forward Rate of Return (Yacktman) % | -17.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BGI Genomics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 4,032.12 | ||
| EPS (TTM) (Â¥) | -0.244 | ||
| Beta | 1.62 | ||
| Volatility % | 47.28 | ||
| 14-Day RSI | 47.06 | ||
| 14-Day ATR (Â¥) | 1.809973 | ||
| 20-Day SMA (Â¥) | 46.944 | ||
| 12-1 Month Momentum % | -7.16 | ||
| 52-Week Range (Â¥) | 33 - 56.89 | ||
| Shares Outstanding (Mil) | 415.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BGI Genomics Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BGI Genomics Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
BGI Genomics Co Ltd Frequently Asked Questions
What is BGI Genomics Co Ltd(SZSE:300676)'s stock price today?
The current price of SZSE:300676 is ¥45.17. The 52 week high of SZSE:300676 is ¥56.89 and 52 week low is ¥33.00.
When is next earnings date of BGI Genomics Co Ltd(SZSE:300676)?
The next earnings date of BGI Genomics Co Ltd(SZSE:300676) is .
Does BGI Genomics Co Ltd(SZSE:300676) pay dividends? If so, how much?
The Dividend Yield %  of BGI Genomics Co Ltd(SZSE:300676) is 0.22% (As of Today), Highest Dividend Payout Ratio of BGI Genomics Co Ltd(SZSE:300676) was 4.44. The lowest was 0.02. And the median was 0.19. The  Forward Dividend Yield % of BGI Genomics Co Ltd(SZSE:300676) is 0.22%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers